Oligosaccharide Linker-Payload for One-Pot ADC Glycan Remodeling
Solution Overview
Problem
Current site-specific conjugation technologies for antibody-drug conjugates (ADCs) based on glycan remodeling are lengthy, cumbersome, and prone to enzyme residue issues, leading to potential product decomposition and adverse byproducts, with limited chemical methodologies for linking oligosaccharides and toxins.
Innovation Solution
A novel oligosaccharide linker-payload compound forms an amide bond with the antibody's glycan chain, enabling a one-pot enzyme catalysis process for site-specific conjugation, simplifying synthesis and reducing adverse byproducts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional multi-step glycan remodeling methods are used for site-specific ADC conjugation, then site-specific attachment is achieved, but the process becomes lengthy and cumbersome with enzyme residue issues
Solution Approach 1:
The patent combines multiple separate enzymatic steps into a single one-pot transglycosylation reaction. The oligosaccharide linker-payload compound is designed to undergo direct transglycosylation with the antibody's N-glycan in one reaction vessel, eliminating the need for sequential deglycosylation-transglycosylation steps and reducing enzyme residue contamination.
Solution Approach 2:
The oligosaccharide linker-payload compound is pre-synthesized with the exact structure needed for the final conjugate. This preliminary preparation of the conjugate allows the in vivo reaction to proceed directly to the final product without requiring multiple intermediate purification and re-conjugation steps.
2Reliability
If existing chemical methodologies are used for linking oligosaccharides and toxins, then conjugation is achieved, but adverse byproducts are generated
Solution Approach 1:
The patent replaces traditional chemical coupling methods (which use reactive chemicals and catalysts that generate byproducts) with an enzymatic transglycosylation mechanism. The enzyme catalyzes the direct transfer of the oligosaccharide linker-payload to the antibody glycan, using the natural glycosidic bond formation pathway that produces no harmful byproducts.
3Ease of manufacture
If random conjugation based on lysine or cysteine residues is used, then ADC production is simplified, but heterogeneity and non-uniform DAR are resulted
Solution Approach 1:
The patent uses the antibody's own N-glycan structures as intermediaries for site-specific conjugation. The oligosaccharide linker-payload compound specifically targets and conjugates to the N-glycan moieties on the antibody, providing a uniform attachment site that maintains both simplicity and precision.
4Adaptability or versatility
If site-specific conjugation based on antibody Fc glycan remodeling is used, then versatility for different antibodies is improved, but enzyme residue and product decomposition issues occur
Solution Approach 1:
The patent optimizes the reaction parameters including pH, temperature, and enzyme concentration to ensure complete and clean transglycosylation. By carefully controlling these parameters, the reaction proceeds to completion without leaving enzyme residues that could cause product decomposition, while maintaining the versatility of the platform across different antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel approach simplifies ADC synthesis, enhances efficiency, and ensures stable, targeted delivery and release of the payload in target cells, overcoming the limitations of existing methods.
Implementation Method 1
A novel oligosaccharide linker-payload compound forms an amide bond with the antibody's glycan chain, enabling a one-pot enzyme catalysis process for site-specific conjugation
Data Source
AI summary
The present disclosure further relates to a linker-payload compound including an oligosaccharide group, especially a disaccharide group, where the oligosaccharide group is linked to the remainder of the compound by an amide bond. The present disclosure further relates to an antibody-drug conjugate (ADC) containing the linker-payload compound, where the glycan chain in an antibody is remodeled with the oligosaccharide moiety in the linker-payload compound. The present disclosure further relates to preparation methods and use of the above-mentioned substances.



